{
    "clinical_study": {
        "@rank": "80707", 
        "acronym": "COSMOS", 
        "arm_group": [
            {
                "arm_group_label": "Corticosteroid with the 50% reduced dose", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Corticosteroid with the maintained dose", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is a multicenter, randomized, comparison, open-label, phase IV study in kidney\n      trasnplant recepients whose immunosupressive regimen is convertied from Cyclosporine with\n      corticosterod to  Advagraf \u00ae with corticosteroid.  The eligible patients will be randomized\n      into either Arm 1 or Arm 2. The Arm 1 will be reduced corticosteroid slowly until 50% lower\n      dose  from 4 weeks to 12 weeks in the Advagraf \u00ae-based immunosuppressive regimen, and the\n      Arm 2 will receive the same corticosteroid dose for 24 weeks with Advagraf \u00ae."
        }, 
        "brief_title": "A Study to Assess the Efficacy and Safety of Advagraf \u00ae Switching From Cyclosporine Between the Group That Was Treated With a 50 % Reduced Corticosteroid and the Group With Maintained Corticosteroid for Stable Kidney Transplant Recipients", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Kidney Transplant", 
        "detailed_description": {
            "textblock": "The primary objective is to assess the changes in the GFR after 24 weeks of treatment\n      between the group that was reduced corticosteroid slowly until 50% lower dose from 4 weeks\n      to 12 weeks and the group with maintained corticosteroid in stable kidney transplant\n      subjects whose regimen was converted from a CyA-based immunosuppressive regimen with\n      corticosteroid to an Advagraf\u00ae-based immunosuppressive regimen with corticosteroid for\n      kidney transplant subjects whose regimen was converted from a CyA-based immunosuppressive\n      regimen.\n\n      The secondary objective is to assess the creatinine clearance rate, acute rejection,\n      satisfaction of medication and safety of the group with a 50% reduced dose of corticosteroid\n      and the group in which the Advagraf \u00ae-based immunosuppressive regimen with maintained\n      corticosteroid."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Had a kidney transplant at least 12 months before his/her enrollment in this\n             study(including a kidney retransplantion)\n\n          -  Underwent a CyA-based immunosuppressive regimen since his/her last transplantation.\n             The CyA dose remained unchanged during the last four weeks before the subject's\n             enrollment.\n\n          -  The immunosuppressive regimen (combination of medications) remained unchanged for a\n             minimum of four weeks before the subject's enrollment.\n\n          -  GFR\u226530 mL/min\n\n        Exclusion Criteria:\n\n          -  Had received an organ transplant other than a kidney\n\n          -  Had an acute rejection episode within 12 weeks before his/her enrollment in this\n             study, or had an acute rejection episode within 24 weeks before his/her  enrollment\n             in this study that required anti-lymphocyte antibody therapy\n\n          -  Had been diagnosed with new-onset malignancy after his/her transplantation, except\n             for basocellular or squamous cell carcinoma of the skin that had been treated\n             successfully\n\n          -  The subject received a kidney transplant from full-HLA identical donor\n\n          -  Known to have FSGS or MPGN Type II as an underlying disease\n\n          -  Has elevated SGPT/ALT and/or SGOT/AST and/or total bilirubin levels \u2265 2 times the\n             upper value of the normal range of the investigated site\n\n          -  Has liver cirrhosis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02034747", 
            "org_study_id": "ADV-KT-13-01"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Corticosteroid with the 50% reduced dose", 
                    "Corticosteroid with the maintained dose"
                ], 
                "description": "oral", 
                "intervention_name": "Advagraf", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Corticosteroid with the 50% reduced dose", 
                    "Corticosteroid with the maintained dose"
                ], 
                "description": "oral", 
                "intervention_name": "Corticosteroid", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclosporins", 
                "Cyclosporine", 
                "Tacrolimus"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Advagraf", 
            "kidney transplant", 
            "Corticosteroide", 
            "Immunosuppresive regimen"
        ], 
        "lastchanged_date": "January 10, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Busan", 
                        "country": "Korea, Republic of"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chungcheongnam-do", 
                        "country": "Korea, Republic of"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Daegu", 
                        "country": "Korea, Republic of"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gyeonggi-do", 
                        "country": "Korea, Republic of"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Incheon", 
                        "country": "Korea, Republic of"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jeollabuk-do", 
                        "country": "Korea, Republic of"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jeollanam-do", 
                        "country": "Korea, Republic of"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ulsan", 
                        "country": "Korea, Republic of"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicenter, Randomized, Comparison, Open-label, Phase IV Study to Assess the Efficacy and Safety of Advagraf \u00ae Switching From Cyclosporine Between the Group That Was Treated With a 50 % Reduced Corticosteroid and the Group With Maintained Corticosteroid for Stable Kidney Transplant Recipients", 
        "overall_official": {
            "affiliation": "Astellas Pharma Inc", 
            "last_name": "Medical Director", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in the GFR before the treatment (baseline) to that on Week 24", 
            "safety_issue": "No", 
            "time_frame": "Baseline and Week 24"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02034747"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in the GFR before the treatment (baseline) to that on Week 12", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 12"
            }, 
            {
                "measure": "Change in the creatinine clearance before the treatment (baseline) to those on Weeks 12 and 24", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 12 and Week 24"
            }, 
            {
                "measure": "Incidence of acute rejection", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 24"
            }, 
            {
                "measure": "Safety assessed by the incidence of adverse events, vital signs and Lab-test", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 24"
            }, 
            {
                "measure": "Physical examinations including cyclosporine related cosmetic side effect", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 24"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Pharma Korea, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}